**Name of journal:** *World Journal of Radiology*

**ESPS Manuscript NO: 8377**

**Columns: MINIREVIEW**

**Role of 18F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma**

Tantiwongkosi B *et al*. Role of PET/CT in head and neck carcinoma

Bundhit Tantiwongkosi, Fang Yu, Anand Kanard, Frank R Miller

**Bundhit Tantiwongkosi,** Division of Neuroradiology, Department of Radiology and Otolaryngology Head Neck Surgery, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, United States

**Bundhit Tantiwongkosi,** Imaging Service, South Texas Veterans Health Care System, San Antonio, TX 78229, United States

**Fang Yu,** Department of Radiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, United States

**Anand Kanard,** Department of Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, United States

**Frank R Miller,** Department of Otolaryngology Head Neck Surgery, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, United States

**Author contributions:** All four authors actively and equally contributed to the writing and editing of the article as well as gathering the necessary illustrations.

**Correspondence to: Bundhit Tantiwongkosi, MD,** Division of Neuroradiology, Department of Radiology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, Mail Code 7800, San Antonio, TX 78229, United States.

tantiwongkos@uthscsa.edu

**Telephone:** +1-210-5673448 **Fax:** +1-210-5670008

**Received:** December 26, 2013  **Revised:** January 21, 2014

**Accepted:** April 9, 2014

**Published online:**

**Abstract**

Head and neck cancer (HNC) ranks as the 6th most common cancer worldwide, with the vast majority being head and neck squamous cell carcinoma (HNSCC). The majority of patients present with complicated locally advanced disease (typically stage III and IV) requiring multidisciplinary treatment plans with combinations of surgery, radiation therapy and chemotherapy. Tumor staging is critical to decide therapeutic planning. Multiple challenges include accurate tumor localization with precise delineation of tumor volume, cervical lymph node staging, detection of distant metastasis as well as ruling out synchronous second primary tumors. Some patients present with cervical lymph node metastasis without obvious primary tumors on clinical examination or conventional cross sectional imaging. Treatment planning includes surgery, radiation, chemotherapy or combinations that could significantly alter the anatomy and physiology of this complex head and neck region, making assessment of treatment response and detection of residual/ recurrent tumor very difficult by clinical evaluation and computed tomography (CT) or magnetic resonance imaging (MRI). 18F-2-fluoro-2-deoxy-*D*-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) has been widely used to assess HNC for more than a decade with high diagnostic accuracy especially in detection of initial distant metastasis and evaluation of treatment response. There are some limitations that are unique to PET/CT including artifacts, lower soft tissue contrast and resolution as compared to MRI, false positivity in post-treatment phase due to inflammation and granulation tissues, etc. The aim of this article is to review the roles of PET/CT in both pre and post treatment management of HNSCC including its limitations that radiologists must know. Accurate PET/CT interpretation is the crucial initial step that leads to appropriate tumor staging and treatment planning.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Head and neck cancer; Positron emission tomography; Computed tomography; Staging; Post treatment; Recurrence

**Core tip:** Positron emission tomography/computed tomography (PET/CT) has proven to be useful in evaluation of carcinoma of unknown primary origin before panendoscopy and biopsy, regional lymph node metastasis and distant metastasis. PET/CT could be the only study that reveals residual or recurrent tumors when the neck anatomy is markedly distorted after treatment.Limitations of PET/CT in evaluation of primary tumor extent are also discussed to alert the radiologists so they may suggest and correlate with appropriate imaging modalities. The article utilizes diagrams and multi planar reconstructed PET/CT from several histopathologically-proven cases with emphasis on imaging and clinical correlation.

Tantiwongkosi B, Yu F, Kanard A, Miller FR. Role of 18F-FDG PET/CT in pre and post treatment evaluation in head and neckcarcinoma. *World J Gastroenterol* 2014;

**Available from:** URL: http://www.wjgnet.com/esps/

**DOI:** http://dx.doi.org/10.3748/wjg.v20.i0.0000

**INTRODUCTION**

Head neck cancers (HNC) are the sixth most common cancer worldwide. It is estimated that there are an annual total of 53640 new head neck (oral cavity, pharynx and larynx) cancer cases and 11520 deaths in the United States in 2013[1]. There are many challenges in diagnosis, pretreatment staging and post treatment evaluation in these patients. The clinical signs and symptoms may be nonspecific and can vary depending on the tumor site in the head and neck (oral cavities, pharynx, larynx, nasal cavity, paranasal sinuses, salivary glands, thyroid and skin). Some cancers are so occult that escape detection by detailed physical examination, endoscopy and conventional cross sectional imaging. Contrast-enhanced computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET)/CT are widely used to determine the presence and extent of the tumors both before and after treatment. However, PET/CT is superior to both CT and MRI in detection of carcinoma of unknown primary (CUP), cervical lymph node metastasis, distant metastasis, residual tumor, recurrent disease and second primary tumors resulting alteration in treatment planning[2-5]. This article aims to review current roles of PET/CT in head neck cancer in both pre treatment staging and post treatment assessment.

PET/CT is useful and approved by the Centers for Medicare and Medicaid Services in patients with HNC for both pre treatment and post treatment phases. Before treatment, PET/CT can be used for delineation of extent of primary tumor (T), detection of an unknown primary tumor origin (T) or synchronous second primary tumor (T), detection of regional lymph node metastasis (N) and detection of distant metastasis (M). After therapeutic treatment, it is proven to be helpful in the assessment of therapy response, detection of residual primary tumor, long-term surveillance for recurrence in both the primary site and metastatic lymph nodes as well as the detection of distant metastases.

**PRE-TREATMENT EVALUATION**

Standard staging of HNSCC follows the systematic TNM classification per American Joint Committee on Cancer seventh edition[6]. The primary tumor extension (T stage) varies from site to site given differences in specific anatomic detail of each site, while regional lymph node involvement (N0 to N3 stage) shares similar classification with the exception of thyroid and nasopharyngeal cancers. Metastasis outside head neck regions (*e.g.,* mediastinal and axillary lymph nodes) represents distant metastasis (M stage)[6]. Precise tumor staging is critical for treatment planning and prognosis. Prior to initiation of treatment, HNSCC is clinically staged by using clinical examination, imaging, and endoscopy with tissue biopsy or fine needle aspiration. Multiple studies suggest that PET/CT is superior to conventional imaging (CT or MRI) in initial staging and may alter management and treatment especially when unexpected cervical lymph node and/or distant metastasis is discovered[2,5]. National Comprehensive Center Network issued an update in clinical practice guidelines in head neck cancer and PET/CT imaging in 2013 and suggested using PET/CT for initial staging of the oral cavity, oropharyngeal, hypopharyngreal, glottic, and supraglottic cancers for stage III-IV disease as well as mucosal melanoma and nasopharyngeal carcinoma (WHO class 2-3 and N2-3 diseases)[7].

***Primary tumor staging (T)***

The T stage of each site is determined by the size of the primary tumor and invasion into the deep structures[6]. Contrast enhanced CT and MRI have been the primary imaging modalities for evaluating T stage of HNSCC due to their superior anatomic resolution and tissue contrast as compare to PET/CT performed without intravenous (IV) contrast. PET/CT performed with IV contrast provides both anatomic and metabolic details at the same time. However, there is no clear recommendation for routine use of PET/CT in initial T staging. Ha *et al*[2] found that PET/CT upstaged T staging in 2 of 36 patients (5.5%) with subsequent changes in treatment planning. A prospective study by Scott and colleagues showed that PET changed T staging in 6 of 71 patients (8.5%)[5]. MRI remains the preferred imaging method in the assessment of nasopharynx, oral cavity, perineural spread and bone marrow invasion[8,9] while CT is the modality of choice for the larynx and bony cortex invasion[10].

***Oral cavity and oropharynx***

Dental amalgam artifact is a unique problem for CT imaging in the oral cavity and oropharynx. When severe, it can obscure the entire tumor particularly in the oral cavity. PET and MRI are less affected by this type of artifact (Figure 1). MRI, however, is prone to motion artifact given it requires more imaging time. PET/CT also has a high false positivity due to normal lymphoid tissue uptake in the Waldeyer’s ring. Seitz and colleagues did not find additional value of PET/CT to MRI in T staging of oral cavity and oropharyngeal cancers using histopathology as the gold standard. This is thought to be due to limited resolution of PET/CT in detection of small, superficial lesions and lesions obscured by dental artifact[11]. PET/CT has unique benefits in that it can reveal the full tumor extent when the tumor is ill-defined with submucosal extension and diffuse infiltration. This can help the clinician in differentiating tumor border versus normal tissue planes (Figure 2).

A particular concern in the oral cavity is assessing mandibular/bone involvement. Superficial mandibular involvement by a resectable oral cavity cancer is often treated by marginal mandibulectomy while gross mandibular invasion typically requires segmental mandibulectomy with composite free flap reconstruction[12](Figure 3). Metabolic activity seen in the mandible tends to overestimate the presence of the tumor due to partial volume averaging and miscoregistration artifact (Figure 4). The CT portion of the PET/CT and ceCT have more sensitivity and specificity than PET alone in assessment of mandibular invasion[13]. MRI is useful in detection of bone marrow changes as compared to CT. CT is generally superior to MRI in the detection of cortical bone erosion. Overall MRI has similar accuracy as compared to CT and PET/CT. Accuracy is increased when the information of multiple imaging modalities are analyzed if available[14].

Routinely CT is performed with the patient’s mouth close and in neutral position. Apposition of oral cavity and oropharyngeal structures can obscure the tumors. CeCT with dynamic maneuvers (puffed cheek technique, open mouth position or modified Valsava maneuver) can delineate the presence and extent of the lesions[15]. The puffed cheek technique performed during PET/CT scanning has been proven to be practical and improved lesion detection[16].

***Nasopharynx***

MRI is known to be superior to PET/CT for the assessment of locoregional invasion (parapharyngeal space, skull base, intracranium, sphenoid sinus) and retropharyngeal nodal metastasis by nasopharyngeal carcinoma[9]. PET/CT tends to underestimate the extent and volume of tumor in the nasopharynx, skull base, brain and orbits as compare to MRI (Figure 5) which could have significant impact on staging or treatment planning especially when the discordance is outside the nasopharynx[17]. Similar limitations of PET/CT are also noted in pediatric nasopharyngeal carcinoma patients[18]. However PET/CT can be very helpful in identification of a subtle but focally hypermetabolic nasopharyngeal carcinoma when CT and MRI findings are not obvious (Figure 6). In addition PET/CT has the advantage of screening for distant metastatic disease.

***Larynx***

In primary laryngeal tumors the invasion of the preepiglottic fat and the paraglottic fat by laryngeal carcinoma (T3) increases the risk of regional lymph node metastasis. These tumors tend to have a higher recurrence rate and worse outcome when it invades the thyroid or cricoid cartilages (particularly when full thickness cartilage invasion (T4a) occurs[19]. CT is more specific while MRI is more sensitive in detection of cartilage invasion[10]. PET/CT without contrast adds no additional information to CT or MRI with IV contrast (Figure 7). However, pretreatment PET/CT with IV contrast is valuable as a baseline study to compare to the post treatment study[20].

***Perineural spreading***

Perineural spreading occurs when the tumor spreads along the peripheral nerve away from the primary tumor site, and is associated with poor outcomes. The patient may be asymptomatic and it may not be detected during surgery[21]. MRI is the study of choice in detection of perineural spread due to its high tissue contrast. It is important for radiologists to be familiar with PET/CT findings of perineural spreading as some patients may not have MRI as the initial or post treatment evaluation. On PET/CT, perineural spread can present with abnormal linear or curvilinear hypermetabolic activity along the trigeminal or facial nerves[8](Figure 8).

***Detection of CUP origin***

Two to 7% of HNSCC patients present with metastatic cervical lymphadenopathy without definite primary sites[22,23] detected by a complete history (nonspecific symptoms or no symptoms), thorough physical examination/office flexible fiberoptic endoscopy (small submucosal lesion), or conventional contrast enhanced CT/ MRI (small lesion obscured by normal lymphoid tissue). The work up algorithm to search for the primary tumor is shown in Figure 9.

The choice of treatment depends on staging and histology[24]. Failure to identify the primary tumor leads to nontargeted treatment (bilateral tonsillectomies, bilateral neck dissection, radiation to cover the whole pharyngeal mucosa and neck)[25] resulting in increased complication, morbidity and mortality.

Various studies show that PET/CT is able to identify the primary cancer 29% to 54% of cases with 62% to 93% sensitivity, 33% to 93% specificity, 56% to 89% positive predictive value (PPV) and 25% to 96% negative predictive value (NNV)[3,26-31]. The majority of the primary cancers are found in the palatine tonsils or base of tongue[32](Figure 10). A high detection rate of up to 54% can be achieved when the combination of CT, MRI, endoscopy under anesthesia and PET/CT are used. Due to variable negative predictive value of PET/CT, otolaryngologists should still strongly consider panendoscopy with directed biopsy and bilateral tonsillectomies when PET/CT yields negative result[3]. Radiologists should be aware of recent panendoscopy with biopsy before PET/CT. Recent biopsy can cause false-positive result as high as 50%[30]. It is still uncertain when PET/CT should be performed after biopsy to avoid false positivity, therefore if carcinoma of unknown primary is suspected it is best to obtain PET/CT prior to endoscopy and biopsy/tonsillectomy[26,33]. Obtaining PET/CT prior to biopsy may alert the clinician to suspected primary tumor sites and avoid the false positive imaging result if PET/CT is obtained after biopsy.

***Identification of second primary malignancy***

Synchronous SPM occurs within 6 mo when the index primary cancer is detected. Approximately 1.4% to 18%[34] of head neck cancer patients have SPM, especially when the index cancers are laryngeal carcinomas. Most synchronous SPM are found in the lung (Figure 11), head and neck region itself (Figure 12) or esophagus[35] with the majority of the tumors being squamous cell carcinoma[36]. A recent study found that HPV-seropositive patients, especially those who never smoked, have less risk to develop SPM as compared to HPV-seronegative group[37]. Since SPM is one of the main causes of death in early-stage HNSCC, early detection and treatment of SPM increases survival[34]. Detection of SPM also changes treatment planning[33]. A meta-analysis revealed 87.5% sensitivity and 95% specificity of PET/CT in detection of SPM or distant metastasis[38]. Negative PET/CT does not completely exclude the presence of SPM[38].

***Lymph node involvement (N)***

The likelihood of cervical lymph node metastasis in HNSCC depends on location, histology and staging of the primary tumor[39]. The presence of metastatic nodes carries poor prognosis, decreases 5-year survival and necessitates treatment in the neck[40,41]. Differentiation between metastatic lymph nodes and reactive nodes by CT/MR size and morphologic criteria can be difficult[42]. A meta-analysis by Kyzas *et al*[39] showed higher sensitivity/specificity (80%/86%) of PET/CT as compared to other conventional diagnostic modalities (75%/79%). The higher sensitivity is due to the fact that PET can show hypermetabolism in normal-sized metastatic lymph nodes. However PET is not 100% specific because inflammatory reactive nodes and adjacent granulation tissue can increase uptake[43] yielding a false positive result. Radiologists should be aware that small necrotic lymph nodes may appear hypometabolic on PET especially in hyperglycemic patients[44]. Therefore it is important to analyze both morphologic and metabolic information derived from PET/CT (Figure 13).

In HNSCC patients whose metastatic lymph nodes are not palpable on physical examination or visualized on imaging is determined to be clinically N0 (cN0) stage[6]. PET/CT failed to detect half of the cN0 which were confirmed to have metastasis by histopathology. This is thought to be due to small size of occult metastasis beyond resolution of PET (typically micrometastases < 5 mm), obscuration by physiologic glucose uptake in adjacent organs or hyperglycemia. Therefore it is not recommended to routinely use PET/CT to assess possible cervical lymph node metastasis in cN0 setting[39]. However, pretreatment PET/CT may still be useful as an optional imaging to compare with the post treatment scan to discriminate malignant tissue from physiologic uptake[45].

***Distant metastasis (M)***

Approximately 7% to 25% of patients with advanced stage HNSCC have distant metastases at initial presentation[46]. The most common sites of metastasis include lung (Figure 14), bone and abdomen. Mediastinal lymph node involvement is considered distant metastasis[6]. Contrast enhanced chest CT is commonly used to assess intrathoracic spread with 73% sensitivity and 80% specificity[47]. Overall PET/CT is more accurate than conventional imaging in detecting metastatic foci[48]. A meta-analysis by Xu *et al*[49] revealed sensitivity and specificity of PET/CT around 87.5 % and 95% respectively. It is very important to detect distant metastases early in the workup as it changes prognosis and management. Extensive surgery with curative intent may cause significant morbidity and mortality and may be avoided in the event of documented distant metastases. PET/CT is recommended when distant spread is suspected in HNSCC patients with locoregionally advanced stage. However, negative PET/CT does not completely exclude absence of metastasis[49].

***Change in initial staging and management***

Lonneux *et al*[50] performed a multicenter prospective study to evaluate the impact of PET/CT on the initial staging and management of patients with HNSCC. The group found that PET/CT improved the TNM classification of the disease and altered the management of 13.7% of the patients mainly due to the ability of PET/CT to detect metastatic or additional disease.

**POST TREATMENT EVALUATION**

***Therapy response assessment and residual tumor detection***

A small early-stage HNSCC (*e.g.,* a T1N0 true vocal cord carcinoma) can be treated with a single modality[51]. Advanced-staged disease (Stage III and IV) typically needs multimodality treatments including surgery, radiation and chemotherapy[52]. Radical concurrent chemoradiation can be used as a definite therapy in preference to surgery to achieve similar cure rates with less morbidity and to preserve organ function[53]. Surgery and radiation can cause significant inflammation, fibrosis and distortion of the anatomy preventing accurate differentiation between residual tumor and complete tumor response by conventional imaging[54,55]. Inaccurate post treatment assessment may cause delayed or unnecessary treatment resulting in increased mortality and morbidity[45]. Multiple studies have shown that PET/CT is superior to conventional anatomic imaging in assessment of tumor response and detection of residual tumor. This is helpful to the surgeon in selecting the appropriate patients for salvage surgery after CMT[4,56-58].

The sensitivity, specificity, PPV and NPV of PET/CT for detection of residual primary tumor were 94%, 82%, 75% and 95% respectively[4]. It is noted that PET/CT has very high NPV, therefore negative result highly suggests absence of viable residual disease in both primary site and neck (Figures 15 and 16). The low PPV is due to treatment-related FDG-avid inflammation or infection (Figure 17). A positive PET/CT result in the post treatment phase needs careful correlation with clinical information and corresponding CT/MRI findings[45]. It is suggested that PET/CT should be performed no sooner than 2 mo after completion of treatment to avoid false positive results; however it may be performed sooner if there is clinically suspected recurrent disease[59]. We generally recommend performing PET/CT around 3 mo after completion of treatment at our institution.

***Long-term surveillance***

The purpose of obtaining PET/CT as a surveillance tool is to allow for the early detection of recurrent disease (both in the primary site and the neck) (Figure 18), assess for a metachronous second primary tumor (Figure 19) and to rule out distant metastases (Figure 20). PET/CT has 93% to 100% sensitivity and 63% to 94% specificity in detection of recurrent tumor in both primary site and the neck respectively[45,60,61]. The NPV of a single PET/CT and double PET/CT (obtained within 6 mo period) are 91% and 98% respectively. Negative results of two consecutive PET/CT studies could potentially eliminate the need for routine post treatment imaging if there is no clinical suspicion of tumor recurrence[62]. In addition there are no differences in survival between PET/CT detected and clinically detected recurrences[63]. Although there is an appreciable radiation dose and lifetime cancer risk associated with PET/CT, the use of this examination is warranted when utilized in the appropriate clinical setting[64].

Metachronous SPT may occur after 6 mo of the index primary tumor with 2.8% annual rate[65](Figure 21). The incidence of distant metastasis following definitive treatment is 9% with the risk increased in patients with locally advanced stages[65,66]. Overall 17.9% of HNSCC patients develop second primary cancers and/or distant metastasis, especially in patients with recurrent diseases[38,66]. The identification of distant metastatic lesions at the time of restaging recurrent tumors may allow the clinician to avoid aggressive surgery and focus on palliative chemoradiation options [66]. PET/CT has strong utility in detecting second primary tumors or distant metastases with a sensitivity and specificity of 88.8% and 95.1% respectively[38].

**CONCLUSION**

In the pre-treatment phase, PET/CT is useful in the evaluation of patients with carcinoma of unknown primary origin before panendoscopy and biopsy, detection of synchronous second primary tumor, staging of cervical lymph node metastasis and assessing for distant metastases. In the post-treatment phase, it is clear that PET/CT is recommended to assess treatment response, detect residual/ recurrent tumor and rule out distant metastases. Radiologists should carefully analyze both CT and PET information and correlate it with other imaging modalities, previous studies and clinical information.

**REFERENCES**

1 **Siegel R**, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013; **63**: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]

2 **Ha PK**, Hdeib A, Goldenberg D, Jacene H, Patel P, Koch W, Califano J, Cummings CW, Flint PW, Wahl R, Tufano RP. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg* 2006; **132**: 12-16 [PMID: 16415423]

3 **Miller FR**, Hussey D, Beeram M, Eng T, McGuff HS, Otto RA. Positron emission tomography in the management of unknown primary head and neck carcinoma. *Arch Otolaryngol Head Neck Surg* 2005; **131**: 626-629 [PMID: 16027287]

4 **Gupta T**, Master Z, Kannan S, Agarwal JP, Ghsoh-Laskar S, Rangarajan V, Murthy V, Budrukkar A. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging* 2011; **38**: 2083-2095 [PMID: 21853309 DOI: 10.1007/s00259-011-1893-y]

5 **Scott AM**, Gunawardana DH, Bartholomeusz D, Ramshaw JE, Lin P. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. *J Nucl Med* 2008; **49**: 1593-1600 [PMID: 18794254 DOI: 10.2967/jnumed.108.053660]

6 **Edge SB**, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Cancer Staging Handbook From AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010: 39-126

7 **National Comprehensive Cancer Network**. NCCN Clinical Practice Guidelines in Oncology™ 2013. Head and Neck Cancers v. 2.2013. Available from URL: http://www.nccn.org/professionals/physician\_gls/f\_guidelines.asp#head-and-neck

8 **Paes FM**, Singer AD, Checkver AN, Palmquist RA, La Vega GD, Sidani C. Perineural spread in head and neck malignancies: clinical significance and evaluation with 18F-FDG PET/CT. *Radiographics* 2013; **33**: 1717-1736 [PMID: 24108559 DOI: 10.1148/rg.336135501]

9 **Ng SH**, Chan SC, Yen TC, Chang JT, Liao CT, Ko SF, Liu FY, Chin SC, Fan KH, Hsu CL. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. *Eur J Nucl Med Mol Imaging* 2009; **36**: 12-22 [PMID: 18704401 DOI: 10.1007/s00259-008-0918-7]

10 **Zbären P**, Becker M, Läng H. Pretherapeutic staging of hypopharyngeal carcinoma. Clinical findings, computed tomography, and magnetic resonance imaging compared with histopathologic evaluation. *Arch Otolaryngol Head Neck Surg* 1997; **123**: 908-913 [PMID: 9305239]

11 **Seitz O**, Chambron-Pinho N, Middendorp M, Sader R, Mack M, Vogl TJ, Bisdas S. 18F-Fluorodeoxyglucose-PET/CT to evaluate tumor, nodal disease, and gross tumor volume of oropharyngeal and oral cavity cancer: comparison with MR imaging and validation with surgical specimen. *Neuroradiology* 2009; **51**: 677-686 [PMID: 19727695 DOI: 10.1007/s00234-009-0586-8]

12 **Politi M**, Costa F, Robiony M, Rinaldo A, Ferlito A. Review of segmental and marginal resection of the mandible in patients with oral cancer. *Acta Otolaryngol* 2000; **120**: 569-579 [PMID: 11039866]

13 **Goerres GW**, Schmid DT, Schuknecht B, Eyrich GK. Bone invasion in patients with oral cavity cancer: comparison of conventional CT with PET/CT and SPECT/CT. *Radiology* 2005; **237**: 281-287 [PMID: 16118155]

14 **Gu DH**, Yoon DY, Park CH, Chang SK, Lim KJ, Seo YL, Yun EJ, Choi CS, Bae SH. CT, MR, (18)F-FDG PET/CT, and their combined use for the assessment of mandibular invasion by squamous cell carcinomas of the oral cavity. *Acta Radiol* 2010; **51**: 1111-1119 [PMID: 20929295 DOI: 10.3109/02841851.2010.520027]

15 **Henrot P**, Blum A, Toussaint B, Troufleau P, Stines J, Roland J. Dynamic maneuvers in local staging of head and neck malignancies with current imaging techniques: principles and clinical applications. *Radiographics* 2003; **23**: 1201-1213 [PMID: 12975510]

16 **Chang CY**, Yang BH, Lin KH, Liu RS, Wang SJ, Shih WJ. Feasibility and incremental benefit of puffed-cheek 18F-FDG PET/CT on oral cancer patients. *Clin Nucl Med* 2013; **38**: e374-e378 [PMID: 23989442 DOI: 10.1097/RLU.0b013e31826390cf]

17 **King AD**, Ma BB, Yau YY, Zee B, Leung SF, Wong JK, Kam MK, Ahuja AT, Chan AT. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. *Br J Radiol* 2008; **81**: 291-298 [PMID: 18344274 DOI: 10.1259/bjr/73751469]

18 **Cheuk DK**, Sabin ND, Hossain M, Wozniak A, Naik M, Rodriguez-Galindo C, Krasin MJ, Shulkin BL. PET/CT for staging and follow-up of pediatric nasopharyngeal carcinoma. *Eur J Nucl Med Mol Imaging* 2012; **39**: 1097-1106 [PMID: 22532252 DOI: 10.1007/s00259-012-2091-2]

19 Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. *N Engl J Med* 1991; **324**: 1685-1690 [PMID: 2034244]

20 **Chu MM**, Kositwattanarerk A, Lee DJ, Makkar JS, Genden EM, Kao J, Packer SH, Som PM, Kostakoglu L. FDG PET with contrast-enhanced CT: a critical imaging tool for laryngeal carcinoma. *Radiographics* 2010; **30**: 1353-1372 [PMID: 20833855 DOI: 10.1148/rg.305095764]

21 **Liebig C**, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. *Cancer* 2009; **115**: 3379-3391 [PMID: 19484787 DOI: 10.1002/cncr.24396]

22 **Jereczek-Fossa BA**, Jassem J, Orecchia R. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. *Cancer Treat Rev* 2004; **30**: 153-164 [PMID: 15023433]

23 **Miller FR**, Karnad AB, Eng T, Hussey DH, Stan McGuff H, Otto RA. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy. *Head Neck* 2008; **30**: 28-34 [PMID: 17657782]

24 **Calabrese L**, Jereczek-Fossa BA, Jassem J, Rocca A, Bruschini R, Orecchia R, Chiesa F. Diagnosis and management of neck metastases from an unknown primary. *Acta Otorhinolaryngol Ital* 2005; **25**: 2-12 [PMID: 16080309]

25 **Issing WJ**, Taleban B, Tauber S. Diagnosis and management of carcinoma of unknown primary in the head and neck. *Eur Arch Otorhinolaryngol* 2003; **260**: 436-443 [PMID: 12684829]

26 **Rudmik L**, Lau HY, Matthews TW, Bosch JD, Kloiber R, Molnar CP, Dort JC. Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: a prospective clinical trial. *Head Neck* 2011; **33**: 935-940 [PMID: 21674668 DOI: 10.1002/hed.21566]

27 **Yabuki K**, Tsukuda M, Horiuchi C, Taguchi T, Nishimura G. Role of 18F-FDG PET in detecting primary site in the patient with primary unknown carcinoma. *Eur Arch Otorhinolaryngol* 2010; **267**: 1785-1792 [PMID: 20814690 DOI: 10.1007/s00405-010-1371-3]

28 **Dandekar MR**, Kannan S, Rangarajan V, Purandare NC, Chaukar DA, Deshmukh A, D'cruz AK. Utility of PET in unknown primary with cervical metastasis: a retrospective study. *Indian J Cancer* 2011; **48**: 181-186 [PMID: 21768663 DOI: 10.4103/0019-509X.82882]

29 **Padovani D**, Aimoni C, Zucchetta P, Paluzzi A, Pastore A. 18-FDG PET in the diagnosis of laterocervical metastases from occult carcinoma. *Eur Arch Otorhinolaryngol* 2009; **266**: 267-271 [PMID: 18587594 DOI: 10.1007/s00405-008-0733-6]

30 **Johansen J**, Buus S, Loft A, Keiding S, Overgaard M, Hansen HS, Grau C, Bundgaard T, Kirkegaard J, Overgaard J. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. *Head Neck* 2008; **30**: 471-478 [PMID: 18023031]

31 **Wong WL**, Sonoda LI, Gharpurhy A, Gollub F, Wellsted D, Goodchild K, Lemon C, Farrell R, Saunders M. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of occult primary head and neck cancers--an audit and review of published studies. *Clin Oncol (R Coll Radiol)* 2012; **24**: 190-195 [PMID: 22183080 DOI: 10.1016/j.clon.2011.11.001]

32 **Cianchetti M**, Mancuso AA, Amdur RJ, Werning JW, Kirwan J, Morris CG, Mendenhall WM. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. *Laryngoscope* 2009; **119**: 2348-2354 [PMID: 19718744 DOI: 10.1002/lary.20638]

33 **Strobel K**, Haerle SK, Stoeckli SJ, Schrank M, Soyka JD, Veit-Haibach P, Hany TF. Head and neck squamous cell carcinoma (HNSCC)--detection of synchronous primaries with (18)F-FDG-PET/CT. *Eur J Nucl Med Mol Imaging* 2009; **36**: 919-927 [PMID: 19205699 DOI: 10.1007/s00259-009-1064-6]

34 **Kim SY**, Roh JL, Yeo NK, Kim JS, Lee JH, Choi SH, Nam SY. Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. *Ann Oncol* 2007; **18**: 1698-1703 [PMID: 17716985]

35 **Morris LG**, Sikora AG, Hayes RB, Patel SG, Ganly I. Anatomic sites at elevated risk of second primary cancer after an index head and neck cancer. *Cancer Causes Control* 2011; **22**: 671-679 [PMID: 21327458 DOI: 10.1007/s10552-011-9739-2]

36 **Jones AS**, Morar P, Phillips DE, Field JK, Husband D, Helliwell TR. Second primary tumors in patients with head and neck squamous cell carcinoma. *Cancer* 1995; **75**: 1343-1353 [PMID: 7882285]

37 **Peck BW**, Dahlstrom KR, Gan SJ, Caywood W, Li G, Wei Q, Zafereo ME, Sturgis EM. Low risk of second primary malignancies among never smokers with human papillomavirus-associated index oropharyngeal cancers. *Head Neck* 2013; **35**: 794-799 [PMID: 22711172 DOI: 10.1002/hed.23033]

38 **Xu GZ**, Guan DJ, He ZY. (18)FDG-PET/CT for detecting distant metastases and second primary cancers in patients with head and neck cancer. A meta-analysis. *Oral Oncol* 2011; **47**: 560-565 [PMID: 21621450 DOI: 10.1016/j.oraloncology.2011.04.021]

39 **Kyzas PA**, Evangelou E, Denaxa-Kyza D, Ioannidis JP. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. *J Natl Cancer Inst* 2008; **100**: 712-720 [PMID: 18477804 DOI: 10.1093/jnci/djn125]

40 **Snow GB**, Annyas AA, van Slooten EA, Bartelink H, Hart AA. Prognostic factors of neck node metastasis. *Clin Otolaryngol Allied Sci* 1982; **7**: 185-192 [PMID: 7105450]

41 **Whitehurst JO**, Droulias CA. Surgical treatment of squamous cell carcinoma of the oral tongue: factors influencing survival. *Arch Otolaryngol* 1977; **103**: 212-215 [PMID: 849198]

42 **van den Brekel MW**, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J, Meyer CJ, Snow GB. Cervical lymph node metastasis: assessment of radiologic criteria. *Radiology* 1990; **177**: 379-384 [PMID: 2217772]

43 **Kubota R**, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. *J Nucl Med* 1992; **33**: 1972-1980 [PMID: 1432158]

44 **Murakami R**, Uozumi H, Hirai T, Nishimura R, Katsuragawa S, Shiraishi S, Toya R, Tashiro K, Kawanaka K, Oya N, Tomiguchi S, Yamashita Y. Impact of FDG-PET/CT fused imaging on tumor volume assessment of head-and-neck squamous cell carcinoma: intermethod and interobserver variations. *Acta Radiol* 2008; **49**: 693-699 [PMID: 18568563 DOI: 10.1080/02841850802027034]

45 **Mosci C**, DG, Quan A. FDG-PET/CT Initial and Subsequent Therapy Evaluation: Progressing to PET/MR Imaging. *PET Clin* 2012; **7**: 369-380

46 **Gourin CG**, Watts TL, Williams HT, Patel VS, Bilodeau PA, Coleman TA. Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer. *Laryngoscope* 2008; **118**: 671-675 [PMID: 18197136 DOI: 10.1097/MLG.0b013e3181625737]

47 **Brouwer J**, de Bree R, Hoekstra OS, Golding RP, Langendijk JA, Castelijns JA, Leemans CR. Screening for distant metastases in patients with head and neck cancer: is chest computed tomography sufficient? *Laryngoscope* 2005; **115**: 1813-1817 [PMID: 16222201]

48 **Yoo J**, Henderson S, Walker-Dilks C. Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer. *Clin Oncol (R Coll Radiol)* 2013; **25**: e33-e66 [PMID: 23021712 DOI: 10.1016/j.clon.2012.08.007]

49 **Xu GZ**, Zhu XD, Li MY. Accuracy of whole-body PET and PET-CT in initial M staging of head and neck cancer: a meta-analysis. *Head Neck* 2011; **33**: 87-94 [PMID: 20848421 DOI: 10.1002/hed.21400]

50 **Lonneux M**, Hamoir M, Reychler H, Maingon P, Duvillard C, Calais G, Bridji B, Digue L, Toubeau M, Grégoire V. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. *J Clin Oncol* 2010; **28**: 1190-1195 [PMID: 20124179 DOI: 10.1200/JCO.2009.24.6298]

51 **Spector JG**, Sessions DG, Chao KS, Haughey BH, Hanson JM, Simpson JR, Perez CA. Stage I (T1 N0 M0) squamous cell carcinoma of the laryngeal glottis: therapeutic results and voice preservation. *Head Neck* 1999; **21**: 707-717 [PMID: 10562683]

52 **Price KA**, Cohen EE. Current treatment options for metastatic head and neck cancer. *Curr Treat Options Oncol* 2012; **13**: 35-46 [PMID: 22252884 DOI: 10.1007/s11864-011-0176-y]

53 **Sherriff JM**, Ogunremi B, Colley S, Sanghera P, Hartley A. The role of positron emission tomography/CT imaging in head and neck cancer patients after radical chemoradiotherapy. *Br J Radiol* 2012; **85**: e1120-e1126 [PMID: 22744325 DOI: 10.1259/bjr/20976707]

54 **Bronstein AD**, Nyberg DA, Schwartz AN, Shuman WP, Griffin BR. Soft-tissue changes after head and neck radiation: CT findings. *AJNR Am J Neuroradiol* 1989; **10**: 171-175 [PMID: 2492719]

55 **Laubenbacher C**, Saumweber D, Wagner-Manslau C, Kau RJ, Herz M, Avril N, Ziegler S, Kruschke C, Arnold W, Schwaiger M. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. *J Nucl Med* 1995; **36**: 1747-1757 [PMID: 7562038]

56 **Andrade RS**, Heron DE, Degirmenci B, Filho PA, Branstetter BF, Seethala RR, Ferris RL, Avril N. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. *Int J Radiat Oncol Biol Phys* 2006; **65**: 1315-1322 [PMID: 16750327]

57 **Kitagawa Y**, Nishizawa S, Sano K, Ogasawara T, Nakamura M, Sadato N, Yoshida M, Yonekura Y. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. *J Nucl Med* 2003; **44**: 198-206 [PMID: 12571209]

58 **Lell M**, Baum U, Greess H, Nömayr A, Nkenke E, Koester M, Lenz M, Bautz W. Head and neck tumors: imaging recurrent tumor and post-therapeutic changes with CT and MRI. *Eur J Radiol* 2000; **33**: 239-247 [PMID: 10699740]

59 **Nakamura S**, Toriihara A, Okochi K, Watanabe H, Shibuya H, Kurabayashi T. Optimal timing of post-treatment [18F]fluorodeoxyglucose-PET/CT for patients with head and neck malignancy. *Nucl Med Commun* 2013; **34**: 162-167 [PMID: 23196675 DOI: 10.1097/MNM.0b013e32835bdfe3]

60 **Li P**, Zhuang H, Mozley PD, Denittis A, Yeh D, Machtay M, Smith R, Alavi A. Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography. *Clin Nucl Med* 2001; **26**: 131-135 [PMID: 11201470]

61 **Fischbein NJ**, AAssar OS, Caputo GR, Kaplan MJ, Singer MI, Price DC, Dillon WP, Hawkins RA. Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. *AJNR Am J Neuroradiol* 1998; **19**: 1189-1196 [PMID: 9726451]

62 **McDermott M**, Hughes M, Rath T, Johnson JT, Heron DE, Kubicek GJ, Kim SW, Ferris RL, Duvvuri U, Ohr JP, Branstetter BF. Negative predictive value of surveillance PET/CT in head and neck squamous cell cancer. *AJNR Am J Neuroradiol* 2013; **34**: 1632-1636 [PMID: 23639557 DOI: 10.3174/ajnr.A3494]

63 **Ho AS**, Tsao GJ, Chen FW, Shen T, Kaplan MJ, Colevas AD, Fischbein NJ, Quon A, Le QT, Pinto HA, Fee WE, Sunwoo JB, Sirjani D, Hara W, Yao M. Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. *Cancer* 2013; **119**: 1349-1356 [PMID: 23225544 DOI: 10.1002/cncr.27892]

64 **Huang B**, Law MW, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. *Radiology* 2009; **251**: 166-174 [PMID: 19251940 DOI: 10.1148/radiol.2511081300]

65 **Jovanovic A**, van der Tol IG, Kostense PJ, Schulten EA, de Vries N, Snow GB, van der Waal I. Second respiratory and upper digestive tract cancer following oral squamous cell carcinoma. *Eur J Cancer B Oral Oncol* 1994; **30B**: 225-229 [PMID: 7950835]

66 **Gourin CG**, Watts T, Williams HT, Patel VS, Bilodeau PA, Coleman TA. Identification of distant metastases with PET-CT in patients with suspected recurrent head and neck cancer. *Laryngoscope* 2009; **119**: 703-706 [PMID: 19205017]

**P-Reviewers:** Boffano P, Leonardi M, Liu YY, Schoenhagen P **S-Editor:** Gou SX

**L-Editor: E-Editor:**

**Figure 1 Dental amalgam artifact obscuring an oral cavity tumor.** The T2 left lateral oral tongue squamous cell carcinoma (white arrow) was obscured by the dental amalgam artifact on contrast-enhanced computed tomography (CT) (A). The lesion is better evaluated on the contrast-enhanced T1W (B) and positron emission tomography/CT (PET/CT) (C) images. Information from the PET portion is clearly less affected by streak artifact. However, PET/CT does not add additional information to MRI in terms of primary oral cavity lesion extent for the majority of cases.

**Figure 2 Positron emission tomography/computed tomography for delineation of oral cavity tumor extent.** A T4a oral and base of tongue squamous cell carcinoma (green arrow) diffusely and symmetrically infiltrates the ventral aspect of the tongue, whose margins are difficult to appreciate on contrast enhanced computed tomography (CT) (A, B). On the other hand, positron emission tomography/CT (PET/CT) (C, D) clearly demarcates the tumor extent.

**Figure 3 Positron emission tomography/computed tomography for detection of mandibular invasion.** A T4a floor of mouth squamous cell carcinoma (white arrow) with through-and-through involvement (red arrow) of the anterior mandible is demonstrated on axial contrast-enhanced computed tomography (CT) (A: Soft tissue window; B: Bone window), axial contrast-enhanced magnetic resonance imaging (C: T1WI; D: Post contrast enhanced T1WI with fat saturation), and positron emission tomography/CT (E: Axial; F: Sagittal).

**Figure 4 Shine-through artifact on positron emission tomography/computed tomography.** A T4a floor of mouth squamous cell carcinoma (black arrow) appeared to extend to involve the lingual cortex of the mandible seen on positron emission tomography/computed tomography (CT) (A), which is in fact artifactual. The corresponding CT (B) bone window and intraopertive findings confirmed an intact mandibular cortex.

**Figure 5 Positron emission tomography/computed tomography underestimates size and extension of the nasopharyngeal carcinoma and retropharyngeal lymph nodes compared to magnetic resonance imaging.** The approximate lateral extension (red arrow) of the nasopharyngeal carcinoma is well demarcated on magnetic resonance imaging (MRI) (A). The tumor appears to be smaller on positron emission tomography/computed tomography (CT) (B) as compared to MRI because the lateral portion of the tumor is hypometabolic. Inferior to the primary tumor site, there is metastatic bilateral retropharyngeal lymphadenopathy (yellow and green arrows). The full extent of retropharyngeal lymph node involvement is better assessed by MRI (C) than CT (D). Only the right lateral node (yellow arrow) is 2-fluoro-2-deoxy-*D*-glucose avid.

**Figure 6 Positron emission tomography/computed tomography for detection of small submucosal nasopharyngeal carcinoma when computed tomography and MRI are unrevealing in a patient presenting with metastatic cervical lymphadenopathy.** Endoscopy was unremarkable. There was slight enhancement in the left side of the nasopharynx (purple arrow) seen on magnetic resonance imaging (A) without abnormality on computed tomography (CT) (B). Positron emission tomography/CT (PET/CT) (C, D) revealed a focal hypermetabolic region in the left side of the nasopharynx (purple arrow), suspicious for a submucosal tumor. Hypermetabolic left-sided cervical lymphadenopathy was also noted (green arrow). Biopsy revealed squamous cell carcinoma at the site of hypermetabolic activity in the left nasopharynx directed by PET/CT.

**Figure 7 Laryngeal cartilage invasion.** A large T4a squamous cell carcinoma of the larynx with through-and-through cricoid cartilage invasion (blue arrow) and extralaryngeal invasion (red arrow) demonstrated on both positron emission tomography/computed tomography (CT) (A) and contrast-enhanced CT (B).

**Figure 8 Perineural spread.** Positron emission tomography/computed tomography (A: Axial; B: Coronal; C: Axial; D: Sagittal) demonstrates a T4b right oropharyngeal squamous cell carcinoma (green arrow) spreading along the mandibular branch of the trigeminal nerve (yellow) through the right foramen ovale (red arrow) to involve the right cavernous sinus (black arrow). The left mandibular nerve in the foramen ovale is normal (blue arrow).

**Figure 9 Algorithm in diagnosis and management of carcinoma of unknown primary.**

**Figure 10 Carcinoma of unknown primary.** The patient presented with palpable right level IIa lymphadenopathy (blue arrow). FNA of the lymph node was positive for squamous cell carcinoma. Panendoscopy without biopsy and contrast-enhanced computed tomography (CT) (A) were unremarkable. Positron emission tomography/CT (B) showed a small hypermetabolic area in the right palatine tonsil (red arrow) proven to be squamous cell carcinoma by biopsy.

**Figure 11 Synchronous second primary malignancy in the lung.** A T4a supraglottic squamous cell carcinoma (red arrow) with extralaryngeal invasion is well demonstrated on computed tomography (CT) (A) and positron emission tomography/ CT (B). There is a 3-cm hypermetabolic second primary squamous cell carcinoma (yellow) in the right lung apex, discovered at the same time in this patient who had an extensive smoking and drinking history. The rest of the exam is unremarkable.

**Figure 12 Synchronous second primary malignancy in the head and neck region.** A T4b right retromolar trigone squamous cell carcinoma involving the masticator space (blue arrow) was seen on positron emission tomography/computed tomography (PET/CT) (A). There was another second primary tumor in the right aryepiglottic fold (green arrow) causing no symptoms, demonstrated by both PET/CT (B, C) and contrast-enhanced CT (D).

**Figure 13 Hypometabolic necrotic lymph node.** A T1N1M0 right glossopharyngeal sulcus squamous cell carcinoma (red arrow) is FDG avid on positron emission tomography/computed tomography (PET/CT) (A). There is a 1.7-cm necrotic right level IIA lymph node seen on contrast-enhanced CT (B). The necrotic lymph node is hypometabolic and may potentially cause a false negative result if the CT portion of the PET/CT or corresponding contrast-enhanced CT were not correlated.

**Figure 14 Lung metastasis at initial staging.** A T3N2bM1 right base of tongue squamous cell carcinoma (black arrow) was FDG avid on positron emission tomography/computed tomography (A-D) with metastasis to the right level IIA (red arrow) and lung (blue arrow).

**Figure 15 Complete treatment response at the primary tumor site.** A T2N0M0 oral tongue squamous cell carcinoma (yellow arrow) seen on contrast-enhanced computed tomography (CT) (A) and positron emission tomography/CT (PET/CT) (B) showed complete response after 3 mo of chemoradiation demonstrated on PET/CT (C). The tumor is no longer hypermetabolic. The patients remained disease free for 3 years, proving true negative result of PET/CT.

**Figure 16 Complete response of a metastatic lymph node.** A T2N2bM0 right palatine tonsil squamous cell carcinoma (red arrow) and right level IIA metastatic lymph node (yellow arrow) were seen on both contrast-enhanced computed tomography (CT) (A) and positron emission tomography/CT (PET/CT) (B). After chemoradiation, the node was smaller on contrast-enhanced CT at 6 wk (C) and hypometabolic on PET/CT at 4 mo (D), representing complete response to treatment. Negative physical examination and PET/CT at 1 year (E) confirmed true negative result of the PET/CT performed at 4 mo.

**Figure 17 False positive positron emission tomography /computed tomography result due to post treatment infection.** A T3N0M0 left supraglottic squamous cell carcinoma showed edema and necrosis at the tumor site (red arrow) on contrast-enhanced computed tomography (CT) (A, B) at 5 wk after chemoradiation and increased uptake onpositron emission tomography/CT (PET/CT) (C, D) at 10 weeks. The patient had severe throat pain and fever. A residual tumor cannot be excluded, therefore endoscopy with biopsy was performed showing radiation-induced inflammation, tumor necrosis and superimposed actinomycosis causing a false positive result on PET/CT. Due to lack of viable tumor, no salvage surgery was performed. The patient was disease free at two-year follow up.

**Figure 18 Recurrent primary tumor detected by positron emission tomography/computed tomography.** A T3N0M0 right palatine tonsil squamous cell carcinoma was demonstrated on axial T2W magnetic resonance imaging (MRI) (A) and coronal contrast-enhanced T1W MRI (B). MRI and positron emission tomography /computed tomography (PET/CT) performed 2 and 3 mo after completion of chemoradiation demonstrated complete treatment response (not shown). Surveilance PET/CT (C, D) revealed intense increase metabolism in the right palatine tonsil and medial pterygoid muscle representing a recurrent SCC.

**Figure 19 Recurrent nodal disease.** A T2N1M0 right hypopharyngeal squamous cell carcinoma status post completed chemoradiation 2.5 years ago with complete response (not shown). The patient presented with right sided level II lymphadenopathy. computed tomography (CT) without contrast (A) showed an ill-defined mass in the right level II. Positron emission tomography/CT (PET/CT) (B) demonstrated very intense metabolism in the mass. Biospy confirmed a recurrent SCC in the right level IIa node.

**Figure 20 Failure of treatment due to distant metastasis.** A T4aN2cM0 right base of tongue squamous cell carcinoma (red arrow) with bilateral level IIA metastatic lymphadenopathy (white and yellow arrows) seen on positron emission tomography/computed tomography (PET/CT) at initial staging (A, B). The patient received chemoradiation. PET/CT (C, D) performed at 3 mo after treatment showed new lung metastases.

**Figure 21 Metachronous second primary tumor.** A T1N0M0 left floor of mouth squamous cell carcinoma (SCC) (not shown) s/p wide local excision with primary closure and selective neck dissection 3 years ago. Surveilance positron emission tomography/computed tomography (A-C) showed a recurent SCC at left floor of mouth (yellow arrow) and two metachronous second primaries at the left hypopharyngx (black arrow) and left base of tongue (red arrow).